NewAmsterdam Pharma Company N.V.

What Do They Do?

Develops oral cholesterol-lowering medicines, including obicetrapib alone or combined with ezetimibe, for people with high cholesterol who remain at cardiovascular risk despite existing treatment.

How Do They Make Money?

Revenue has mainly come from Menarini’s license: an upfront payment for rights and payments for continued development work. The agreement also provides milestone payments when specified goals are met, royalties on product sales, and payments when Menarini buys finished tablets.

Who Are Their Customers?

Menarini holds exclusive rights to commercialize obicetrapib in most European countries if approved. NewAmsterdam plans to commercialize directly in the United States if approved and may work with partners in other regions.

Do Revenues Turn Into Profits?

No. It lost $203.8M in FY2025.

How Are They Changing?

Who Do They Compete With?

Competes with Merck &, AstraZeneca, Arrowhead Pharmaceuticals, CVI Pharmaceuticals, Innovent Biologics, Ionis Pharmaceuticals, Lib Therapeutics, Novartis, Novo Nordisk, Regeneron Pharmaceuticals, and Verve Therapeutics